Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.

This study suggests that sugemalimab in combination with a chemotherapy regimen is more effective but not economical for patients with metastatic non-small cell lung cancer receiving first-line therapy in China and that a reasonable reduction in drug prices could improve the probability of it being economical.